Hortons neuralgia Suicide headache
Conditions
Interventions
GON-injection (as part of regular treatment)
Sponsors
Leids Universitair Medisch Centrum
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: - Patients have to be diagnosed with episodic or chronic cluster headache according to the international classification of headache disorders * third edition, ICHD-3 - Patients have to be aged 18-75 years - Patients should be receiving a GON-injection as regular therapy for episodic or chronic cluster headache
Exclusion criteria
Exclusion criteria: Treatment with a SPG-stimulator or an occipital nerve stimulator
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary endpoint of this study is the difference in mean ipsilateral R2 latency of the blink reflex between the one-week and baseline timepoint. | — |
Secondary
| Measure | Time frame |
|---|---|
| * Clinical response to GON-injection as measured by daily attack frequency, attack intensity and duration * The association between the mean ipsi- and contralateral R2 latency of the blink reflex and the clinical response, as measured in percentage change in attack frequency, to the GON-injection * The association between the mean ipsi- and contralateral AUC of the blink reflex and the clinical response to the GON-injection * The change in ipsi- and contralateral mean R2 latency and mean AUC between all 4 time points * The difference in mean trigeminal sensible and pain threshold between all 4 time-points * The association between trigeminal sensible and pain threshold and clinical response to the GON-injection | — |
Countries
Netherlands
Outcome results
None listed